Navigation Links
$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope
Date:9/11/2008

WALNUT CREEK, Calif., Sept. 11 /PRNewswire/ -- A project to advance research and improve treatments for fragile X syndrome will be funded by a new $1.6 million, three-year cooperative agreement with the Center for Disease Control (CDC) and others.

The agreement, intended to bring better care to the more than 100,000 affected Americans, is between The National Fragile X Foundation (NFXF), the CDC's National Center on Birth Defects and Developmental Disabilities, the Association of University Centers on Disabilities, the New York State Institute for Basic Research in Developmental Disabilities and the Data Coordinating Center at Columbia University.

Fragile X syndrome is the most common known cause of inherited intellectual disability and the most common known single gene cause of autism.

The effort will advance the core activities of the Fragile X Clinical and Research Consortium (FXCRC). The NFXF initiated the FXCRC in 2006 to advance clinical practice and facilitate coordinated, collaborative multi-site research. The FXCRC has been meeting regularly since its inception to address best practices in evaluation and treatment, including pharmacological, therapeutic and educational treatments, strategies for supporting and enhancing clinic work, and research priorities. The NFXF prioritized its support of a clinics consortium when it realized the body of Fragile X expertise was scattered throughout North America and organizing that expertise would enhance existing and future research efforts while simultaneously making clinical evaluation and treatment more easily accessible to families.

"The fact the consortium has moved from concept to reality to government funding so quickly is a testament to the organization, its leadership and the families that each year travel to Washington, D.C., to urge Congress to support this important cause," said Jeffrey Cohen, chair, NFXF Public Policy Committee, and father of a son and daughter with fragile X syndrome.

The FXCRC will also address other related conditions such as fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency which potentially impact over one million adult male and female carriers in the U.S.


'/>"/>
SOURCE The National Fragile X Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
2. Yongye Biotechnology International Raises $9.4 Million in Private Placement
3. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
6. Proteolix Raises $79 Million in Series C Financing
7. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
8. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
9. Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
10. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016   ... a biopharmaceutical company focused on the development and commercialization of ... the 18 th Annual BIO CEO & Investor ... EST in New York, NY . ... provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
Breaking Biology Technology:
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
(Date:1/20/2016)... A market that just keeps on growing. Molecular Diagnostics ... genomics knowledge. Learn all about it in this new ... trends are pushing market growth and company valuations. Trends ... pathogen evolution - next generation sequencing - emergence of ... the role of genetic material in Disease and Health ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):